LRMR

Larimar Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↓ 3/10
Larimar Therapeutics sales and earnings growth
LRMR Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -70.18%
  • FCF Y/Y↓ -64.59%
Larimar Therapeutics gross and profit margin trends
LRMR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -119.70%
Larimar Therapeutics net debt vs free cash flow
LRMR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Larimar Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗